GSK and Hanmi Pharma of Korea to Develop Drugs for China

GlaxoSmithKline and Hanmi Pharmaceutical, a Korean biopharma, have agreed to co-develop and co-market drugs that they call Evidence Based Formulation (EBF) products. The two companies will co-market their products in Korea and China, while GSK will be responsible for selling them in other territories. According to the agreement, Hanmi will perform the formulation research, early clinical studies and manufacturing; GSK will be in charge of late-stage clinical studies and registrations. More details.... Stock Symbol:  (NYSE: GSK) Share this with colleagues: // //